Regeneron Rises 6.7% in Early Trading Following Analyst Buy Recommendation

Deep News10-01

In early Wednesday trading, Regeneron Pharmaceuticals (REGN), an S&P 500 component stock, surged 6.7%. The company is experiencing revenue growth from its core products, which is now offsetting the decline in revenue from its previous blockbuster drugs. Analysts have recommended the stock as a buy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment